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ABSTRACT  The two most common entities among generally rare but 
under-diagnosed autoinflammatory bone disorders are chronic recur-
rent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hy-
perostosis, and osteitis (SAPHO) syndrome. Due to their similarities, many 
authors consider CRMO to be a subtype of SAPHO syndrome. The aim of 
this study was to compare clinical, laboratory, and imaging features and 
outcomes of patients with CRMO and SAPHO. The analysis of the data 
from 6 children with CRMO (four girls and two boys, age 3.5-14 years) 
and of 6 children (6 boys, age 13.5-17.5 years) with SAPHO syndrome was 
performed. The initiating symptoms in all patients with CRMO were bone 
pain with multifocal bone lesions. There were no skin manifestations. 
Five out of six patients achieved control with nonsteroidal anti-inflam-
matory drugs (NSAIDs) and corticosteroids, while one patient required 
disease-modifying antirheumatic drugs (DMARDs). The initiating symptom 
in five patients with SAPHO syndrome were severe acne, while in one pa-
tient acne occurred two years after the disease onset. Two patients typi-
cally developed inflamed sternoclavicular joints and sternum, while the 
others showed changes affecting other skeletal regions. Three patients 
achieved control with NSAIDs and corticosteroids, the others required 
DMARDs and TNFα inhibitors. In comparison with patients with CRMO, 
patients with SAPHO suffered more frequent and longer lasting exac-
erbations. In conclusion, CRMO and SAPHO syndrome have an array of 
common characteristics, but also a number of differences. Nevertheless, 
further investigation into the etiopathogenesis is required to establish a 
definite relationship between CRMO and SAPHO.
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INTRODUCTION
Autoinflammatory bone disorders are a group of 
diseases characterized by a nonspecific inflamma-
tory reaction whose trigger is most likely the inap-
propriate activation of the innate immune system 
(1-4). This group of disorders includes SAPHO syn-
drome (synovitis, acne, pustulosis, hyperostosis, and 
osteitis), chronic recurrent multifocal osteomyelitis 
(CRMO), Majeed syndrome, deficiency of the interleu-
kin-1-receptor antagonist (DIRA), pyogenic arthritis, 
pyoderma gangrenosum, and acne syndrome (PAPA) 
and cherubism. Among the above, SAPHO syndrome 
and CRMO are the most common (2). While the ge-
netics for DIRA, PAPA, and Majeed syndrome are well 
defined, the genetics behind SAPHO syndrome and 
CRMO are still unclear (1). Increased levels of IL1β, 
IL6, IL12, and TNFα as well as decreased levels of IL10 
have been observed, pointing toward dysregulation 
of these pathways and an imbalance between proin-
flammatory and anti-inflammatory cytokines (3,4). 
Due to the uncertain cause and similar features, 
a certain number of authors support the hypothesis 
that CRMO is a pediatric form of the SAPHO syndrome 
(5-7). Whether this is true or CRMO is a separate entity 
is yet to be determined. 
The main characteristic of the SAPHO syndrome is 
osteitis, which may or may not be followed by a spec-
trum of skin lesions (8,9). The syndrome has a chronic 
character with periods of remissions and exacerba-
tions (5). SAPHO syndrome can occur at any age, with 
the prevalence of <1/10000 in Caucasians (5,10–13). 
The anterior chest wall is the most frequently affected 
site. The spine is affected less often, lesions can rarely 
be found in the long bones and the mandible (14,15). 
Uncommonly, only the manubriosternal junction is 
affected, resulting in diagnostic doubts in relation to 
the other causes of chest pain, especially concerning 
the cardiac pathology (16). Arthritis is found in more 
than 90% of the patients, with a preference for the 
axial skeleton (9). Skin manifestations in the form of 
neutrophilic dermatoses (acne conglobata, acne ful-
minans, palmoplantar pustulosis, hidradenitis sup-
purativa, pustular psoriasis, and rarely pyoderma 
gangrenosum and Sweet’s syndrome) (14) can occur 
before, concurrently, or after the onset of osteomus-
cular symptoms. However, the disease can advance 
without any skin manifestations (12,17). 
CRMO is an autoinflammatory disorder causing a 
sterile inflammation of the bone (18). Because of its 
nonspecific clinical and diagnostic findings, incom-
pletely understood pathophysiology and the lack of 
recognition, the diagnosis is often late (19,20). CRMO 
affects children of the median age of 10 years (21-24). 
Initial presentation is usually bone pain varying from 
mild to intense. The most commonly affected areas 
are the metaphysis of the long bones, pelvis, verte-
bral bodies, and clavicles (1,25). However, lesions can 
affect any bone in the body, including the neurocra-
nium (26,27). CRMO can also affect the skin, lungs, 
gastrointestinal system, and eyes (1,2). Due to the 
relapsing and remitting character of the disease, im-
pairment and bone deformation can occur (3). Luck-
ily, whole-body magnetic resonance imaging (MRI) 
has shown a great success in detecting bone changes 
and is recommended at the onset of a disease as well 
as during the follow-up (19,28,29).
PATIENTS AND METHODS
A retrospective medical records review of all pa-
tients suffering from SAPHO syndrome or CRMO aged 
Figure 1. Acne conglobata on the face of patient 1 with SA-
PHO syndrome.
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1-18 years, dating from 2006 to 2016, was performed 
at the Division of Paediatric Immunology and Rheu-
matology, Department of Paediatrics, of the Univer-
sity Hospital Centre Zagreb. The following data were 
collected and analysed: sex, age, date of diagnosis, 
clinical data, laboratory testing, diagnostic results, 
and therapy. The approval of the ethics committee 
was obtained before the data was collected. 
RESULTS
Patients with SAPHO syndrome
Six patients were diagnosed with SAPHO syn-
drome, all boys, with the median age of 16 years 
(13.5-17.5) at the disease onset. All patients pre-
sented with skin manifestations – acne conglobata 
(Figure 1 and Figure 2) – with one patient also having 
pyoderma gangrenosum. Five patients had skin man-
ifestations as the initiating symptom, while in one pa-
tient acne appeared two years after the appearance 
of osteomuscular symptoms, with skeletal pain as the 
initiating symptom (Table 1). Only two patients had 
increased body temperature (patients 1 and 5). Five 
patients experienced lumbosacral pain extending to 
the hips, and three of them also had a typical pain in 
the anterior chest wall. In addition, patient 1 felt pain 
in the left knee, patient 4 in the left shoulder, and pa-
tient 5 in the right leg and cramps in both legs. Labo-
ratory results for every patient showed increased in-
flammatory markers (Table 1).
All patients underwent plain radiography and 
most underwent MRI. The chest wall was affected in 
four out of six patients. There were no lesions of the 
long bones. A technetium 99m (Tc-99m) bone scan 
showed increased tracer uptake in the anterior cos-
tal wall (ACW) in three patients (patients 1, 2, and 5), 
but only two had a typical “bull’s head sign” (patients 
1 and 5) (Figure 3). Other affected locations were the 
sacroiliac joints (patients 1, 2, 5, 6), knees (patients 1, 
5), foot (patient 5), and hand (patient 1). Patient 3 had 
an increased tracer uptake only in the right maxilla 
and mandible. 
Due to acne conglobata as the first symptom in 
five patients, three patients (patients 1, 4, and 5) were 
initially treated with antibiotics (mostly azithromycin 
and clindamycin), but all unsuccessfully. Because of 
the osteoarticular symptoms in all patients, NSAIDs 
were introduced as the first-line therapy, but without a 
satisfying effect in all but one patient (patient 3). Sub-
sequently, patient 1 received DMARDs – sulfasalazine 
and later methotrexate. Patients 2 and 5 were treated 
with corticosteroids and DMARDs; however, patient 
2 eventually needed TNFα inhibitors (etanercept). Pa-
tients 4 and 6 were treated with corticosteroids. All 
patients were also treated with isotretinoin (Table 1). 
Under prescribed therapy, all patients achieved dis-
ease control.
Patients with CRMO
Six patients were diagnosed with CRMO: four girls 
and two boys, of median age 7.5 (3.15-14) at the dis-
ease onset (Table 1). The initiating symptom in five 
patients was bone pain: patients 7 and 12 presented 
with pain in the right leg, while patients 9 and 11 ex-
perienced pain in the back accompanied with high 
fever. Patient 10 presented with pain in the right 
sternoclavicular joint. Patient 8 had impaired walk-
ing capacity and hypotrophy of lower extremities as 
initiating symptoms (Table 1). All patients had multi-
focal inflammatory bone lesions, three of them had 
dominating lesions in the lower extremities (tubu-
lar bones), two in the axial skeleton, and one in the 
clavicle. Only patient 8 had symmetric lesions. No of 
patients with CRMO had skin manifestations or in-
flammatory bowel syndrome. Increased inflamma-
tory markers (CRP, ESR) were noted in four patients, 
followed by increased body temperature (Table 1). 
Plain radiography was performed, followed by 
scintigraphy and MRI in most patients. In patient 7, 
radiography showed lesions of the right tibia and of 
the third metatarsal bone, while scintigraphy showed 
increased tracer uptake in these areas as well as in the 
right mandible, creating a multifocal image. Patient 
8 had multiple lesions of the long bones of the ex-
tremities, spine, ribs, and clavicle, with scintigraphy 
showing a symmetrical multifocal increased tracer 
Figure 3. A technetium 99m (Tc-99m) bone scan showing 
intensive tracer uptake at the sternoclavicular joints and 
sternum, which represent a  typical “bull’s head” sign in pa-
tient 1 with SAPHO syndrome.
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uptake in the long bones of the extremities. MRI and 
scintigraphy confirmed changes in Th12 and L3 in 
patient 9. In patient 10, lesions of the right clavicle, 
sternoclavicular joint and first rib were detected with 
radiography. Inflammatory changes of the vertebra 
and right shoulder in patient 11 were confirmed with 
radiography, MRI, and scintigraphy, while scintigra-
phy showed increased tracer uptake in both tibias in 
patient 12 (Table 1).
All patients were treated with NSAIDs. Patients 9 
and 11 were treated with antibiotics (ceftriaxone or 
amoxicillin with clavulanic acid) because of elevated 
inflammatory markers and fever, but without any ef-
fect. Patients 7 and 12 were simultaneously treated 
with azithromycin due to its anti-inflammatory effect, 
followed by vitamin D3, calcium, and physical thera-
py, alongside NSAIDs, which led to remission. Due to 
the inefficacy of NSAIDs in patients 8 and 9, disease 
control was achieved only after introduction of corti-
costeroids. Patient 10 achieved disease control after 
the introduction of sulfasalazine alongside NSAID, 
while NSAIDs were sufficient in patient 11 (Table 1). In 
the end, disease control was achieved in all patients.
DISCUSSION
SAPHO syndrome
The aim of our study was to analyze and compare 
clinical, laboratory, and imaging features as well as 
the outcomes of patients with CRMO and SAPHO 
syndrome.
The first sign of the SAPHO syndrome is usually 
oscillating, progressive, palpatory skeletal pain (5). 
Our findings were different, as 5 out of 6 patients 
(83%) had skin lesions as the first symptom (Table 1), 
while only one patient had skeletal pain as the initiat-
ing symptom. Skeletal pain occurred after 2 months 
or up to 4 years later in 4 patients. Lumbosacral pain 
occurred in five patients (83%), and anterior chest 
wall pain in three (50%). In a study conducted by Li et 
al., all of 164 patients reported pain in the ACW, and 
67.6% presented with pain in the lumbosacral region 
(11).
Studies have shown that skin manifestations (neu-
trophil dermatoses) (5) appear in a range from 2/3 
(12) to 94.5% of patients (11). They usually develop 
two years prior or after the osteomuscular symptoms 
(5,9,30). In comparison, all of our patients had skin 
manifestations, occurring in five patients as the first 
symptom, whereas in one patient they manifested 
two years after the first osteoarticular symptom. The 
association of noninfectious osteitis and skin chang-
es is often critical for the diagnosis (14,31). While all 
our patients had skin manifestations, unfortunately, 
patients without them were probably left undiag-
nosed or recognized as some other disease (probably 
juvenile spondyloarthritis).
Four out of six patients had lesions in the chest 
wall, which is its most common location. The second 
most common location is the spine, primarily affect-
ing the thoracic segment, which was observed in two 
of our patients (14). Five patients showed symptoms 
of sacroiliitis, which was then followed by osteosclero-
sis of the iliac bone, typical for SAPHO syndrome (8,9).
Only two of our patients presented a typical “bull’s 
head sign” on the skeletal scintigraphy, pathogno-
monic for the syndrome, which are findings similar to 
those of Fu et al. where only 22.9% of patients had 
this sign, suggesting its lack of sensitivity (32,33). 
Due to the similarities between SAPHO syndrome 
and osteomyelitis, the hypothesis that Propionibacte-
rium acnes cases the syndrome, but also because of 
severe acne, patients are often treated with antibiot-
ics (34,35). Studies have shown that this treatment is 
effective only in a low percentage of cases. Moreover, 
the symptoms would reoccur by the end of the ther-
apy (36,37). In our study, three patients were treated 
with antibiotics (mostly azithromycin and clindamy-
cin) with no improvement in skin status.
All of our patients were treated with isotretinoin 
because of its high potency against severe acne (35). 
Our patients were treated with NSAIDs due to the 
osteoarticular symptoms, but NSAIDs were a suffi-
cient treatment only in one patient. Corticosteroids 
and DMARDs were used as the second line of thera-
py (5,14). They were effective in four of our patients, 
while one patient (patient 2) did not achieve sufficient 
control of the disease. In a survey conducted by Li et 
al., 49.0% of patients considered DMARDs effective, 
while 81.2% of patients reported a decrease of pain 
under corticosteroid therapy (11). The disease was 
progressing in patient 2, so a TNFα inhibitor (etaner-
cept) was introduced because of its positive rapid ef-
fect on patients with refractory SAPHO syndrome and 
therapy-resistant acne conglobate (38-41).
CRMO 
The first symptom at the disease onset is usually 
bone pain, which agrees with our findings, in which 
5 out of 6 patients experienced pain as the initiat-
ing symptom, and one patient had walking disability 
and muscle hypertrophy (1). CRMO lesions are most 
often positioned on the clavicle, tibia, femur, fibula, 
and pelvis (3,23,24,42). A lesion on the distal part of 
the tibia was confirmed by radiography in patient 
7, extending to the epiphyseal plate, which is a very 
common location and type of lesion for CRMO (1,42). 
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Three of our patients in the lower extremities (tubular 
bones) and two patients had dominating lesions in 
the axial skeleton. Two out of six patients had lesions 
in the clavicle, which is one of the most commonly 
affected sites (43). 
In cohort studies, 70-99% of patients had multi-
focal lesions, which is in agreement with our study 
(44). All of our patients had multifocal lesions, which 
were symmetric in only one patient. The main goal of 
whole-body imaging is to recognize the multifocal 
and bilateral patterns characteristic for CRMO and to 
diminish the need for biopsy (19,28,29). Unfortunate-
ly, the highly recommended whole-body MRI was not 
available in Croatia during our retrospective study.
Patients 9 and 11 were treated with antibiotics 
(mostly ceftriaxone and amoxicillin with clavulanic 
acid) due to the high inflammatory markers and fever 
but without any effect, which corresponded to oth-
er studies (45). While all patients were treated with 
NSAIDs, patient 7 and 12 were treated simultane-
ously with azithromycin because of its potential anti-
inflammatory and immunomodulatory effect (46). 
Unfortunately, due to the simultaneous treatment 
with NSAID, we cannot assess whether azithromycin 
had any effect. Only patient 11 had a satisfactory re-
sponse to NSAIDs. Corticosteroids were introduced 
into therapy in patients 8 and 9, which is a great 
choice in patients with exacerbations nonreactive to 
NSAIDs (2,3,22). Patient 10 was successfully treated 
with sulfasalazine alongside NSAIDs. 
SAPHO syndrome and CRMO comparison
Whether SAPHO syndrome and CRMO are dis-
tinct diseases or different manifestations of the same 
syndrome has not yet been answered with certainty. 
Considering the fact that CRMO usually affects chil-
dren and SAPHO syndrome usually affects adoles-
cents and adults, some researchers believe CRMO is a 
pediatric form of SAPHO syndrome (5,6). Our patients 
with CRMO were aged between 3.5 and 14.0 years, 
while patients suffering from SAPHO syndrome were 
between 13.5 and 17.5 years, which supports the pro-
posed age preferences of these diseases (2). However, 
there have been records of pediatric patients with 
SAPHO syndrome (6,47) and adults with CRMO (48) 
which, on the other hand, supports the hypothesis of 
the two distinct pathologies with different manifesta-
tions regardless of age. Both SAPHO syndrome and 
CRMO have a marked female predominance, which 
was in agreement with our results regarding patients 
with CRMO (four girls and two boys). However, all our 
patients with SAPHO syndrome were male, differing 
from recent literature and increasing the distinction 
between our two groups (Table 1) (9,11,19,49).
There are a number of similarities between the 
diseases. The lesions are osteodestructive, later os-
teoprolific, and followed by osteitis and hyperostosis. 
The bone biopsy is conclusive with inflammation and 
usually shows a sterile culture. Skin changes and IBD 
are associated with both diseases. However, SAPHO 
syndrome has lesions on the axial skeleton, while 
CRMO has them on the lower extremities near the 
metaphysis of the long bones (50). Notably, some 
studies describe CRMO and SAPHO syndrome as one 
disease, which impedes an objective comparison 
(5,7). The number of patients for this study was lim-
ited and therefore comparison with larger studies is 
more difficult. 
Both groups in this study had almost identical 
symptoms followed by increased inflammatory mark-
ers, occasionally increased body temperature, and 
sterile cultures (Table 1). However, some discrepan-
cies were observed. Patients suffering from SAPHO 
syndrome had lesions on the axial skeleton and acne 
conglobate, while patients with CRMO had multifo-
cal lesions mostly positioned on the tubular bones, 
without skin manifestations. Furthermore, five out of 
six patients with CRMO achieved control with NSAIDs 
and corticosteroids, whereas patients with SAPHO 
syndrome suffered longer and more frequent exacer-
bations and needed DMARDs and TNFα inhibitors to 
achieve control (Table 1). 
The retrospective form of the study, small sample 
size, and differences in age and sex between the two 
groups of patients presented a limitation in execut-
ing our study.
CONCLUSION
There are a number of shared elements between 
CRMO and SAPHO syndrome, but we found a number 
of differences such as sex predominance, skin mani-
festation, bone lesion location, and progression of the 
disease. The occurrence of CRMO predominantly dur-
ing childhood and SAPHO syndrome in adolescence 
is consistent with past studies. At this stage, it is not 
possible to establish with certainty whether SAPHO 
syndrome and CRMO are the same disease. This ques-
tion will be answered with certainty only when the 
inconclusive etiopathogenesis of these two most fre-
quent autoinflammatory bone disorders is revealed.
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